Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Disproportionality Analysis Based on the Japanese Adverse Drug Event Report Database
- 12 July 2018
- journal article
- letter
- Published by American Diabetes Association in Diabetes Care
- Vol. 41 (9) , e130-e132
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance DatabaseBritish Journal of Dermatology, 2016
- Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance databaseJournal of Clinical Pharmacy and Therapeutics, 2016
- Drug‐induced pemphigoid: a review of the literatureJournal of the European Academy of Dermatology and Venereology, 2014
- Dipeptidyl Peptidase-4 Inhibitors Cause Bullous Pemphigoid in Diabetic Patients: Report of Two CasesDiabetes Care, 2011
- The reporting odds ratio and its advantages over the proportional reporting ratioPharmacoepidemiology and Drug Safety, 2004